Search Medical Condition
Please enter condition
Please choose location

Middx, United Kingdom Clinical Trials

A listing of Middx, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (534) clinical trials

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be: - Sutent (prospective) - Inlyta - Sutent (retrospective) - Inlyta - Sutent - not further active treatment (supportive care) ...

Phase N/A

2.71 miles

Learn More »

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

The drug being tested in this study is called IXAZOMIB. IXAZOMIB was being tested to treat people who have relapsed or Refractory Systemic Light Chain (AL) Amyloidosis. The study will enroll approximately 248 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two ...

Phase

3.4 miles

Learn More »

Safety and Biomarker Study of EPI-589 in Parkinson's Disease

This is a within-subject, controlled open-label study seeking to determine if EPI-589 can alter the biochemical signature of PD as assessed by peripheral blood and brain imaging biomarkers. Data will also be collected on disease-relevant clinical measures will be collected.

Phase

3.7 miles

Learn More »

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir. HBeAg-negative subjects will be randomized to receive low or high dose vaccine, in the presence or absence of IC31® adjuvant, or to receive placebo or IC31® ...

Phase

3.7 miles

Learn More »

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Study design: randomized, double-blind, placebo-controlled, multicentre phase 2 proof-of-concept trial of IVA337 for the treatment DcSSc. The treatments are randomly assigned. The randomisation is stratified for background therapy to ensure even distribution of background therapies among treatment groups. There are 3 parallel treatment groups: placebo, IVA337 400mg bid and IVA337 ...

Phase

3.7 miles

Learn More »